The assays are designed to ensure accurate, rapid and cost-effective comparability results for these biosmilars, and include tocilizumab IL-6R neutralization bioassays; a tocilizumab IL-6R binding ELISA; ustekinumab IL-12/IL-23 binding assays; a ustekinumab C1Q binding assay; a ustekinumab neutralization bioassay; ranibizumab VEGF binding assays and a ranibizumab VEGF neutralization bioassay.

Dr Daniel Galbraith, Chief Scientific Officer of BioOutsource, commented that biopharamceutical companies will benefit from a comprehensive range of ready-to-use assays that can be trusted to determine precise comparability results and to expedite drug development programmes.

BioOutsource already has an existing portfolio of assays, and the new additions bring the total molecules supported by the company to nine. BioOutsource is a provider of contract testing services and its R & D Department offers customized assay configuration services to meet specific requirements.

Scottish-based BioOutsource, a provider of contract testing services to monitor the safety and quality of biological drugs and vaccines, was acquired by Sartorius Stedim Biotech in 2015 to better support their global biopharmaceutical clients in fast-tracking new drugs.

Related article
Biosimilars on the horizon

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro PharmaCommunications International. All Rights Reserved.